曲美他嗪治疗肥厚型心肌病心力衰竭的临床效果及其对患者心功能的影响
|
摘要
目的探讨曲美他嗪治疗肥厚型心肌病心力衰竭的临床效果及对患者心功能的影响。方法选择我院2015年8月至2018年3月我院收治的86例肥厚型心肌病心力衰竭患者为研究对象,采用简单随机法将其分为对照组和观察组,各43例。对照组给予常规抗心力衰竭治疗,观察组在此基础上给予患者曲美他嗪治疗,比较两组患者临床效果及心功能的变化。结果观察组治疗总有效率显著高于对照组(P<0.05)。治疗后,两组患者LVEF均升高,LVESd、LVEDd均减小,NT-ProBNP水平均降低,且观察组均优于对照组(P<0.05)。结论在肥厚型心肌病心力衰竭治疗中采用曲美他嗪,效果显著,其能改善患者心功能各项指标,推荐推广。
Objective To investigate the clinical effect of trimetazidine in the treatment of heart failure in hypertrophic cardiomyopathy and its effect on cardiac function of patients. Methods A total of 86 patients with heart failure in hypertrophic cardiomyopathy admitted to our hospital from August 2015 to March 2018 were selected as the research objects and divided into control group and observation group by simple random method, with 43 cases in each group. The control group was treated with routine anti-heart failure treatment, while the observation group was treated with trimetazidine treatment on this basis. The clinical effects of the two groups and changes of cardiac function were compared. Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05). After treatment,the LVEF in both groups increased, the LVESd and LVEDd reduced, the levels of NT-ProBNP decreased, and those in the observation group were better than the control group(P<0.05). Conclusion Trimetazidine is effective in the treatment of heart failure in hypertrophic cardiomyopathy and can improve the indexes of cardiac function of patients, which is recommended to be popularized.
Objective To investigate the clinical effect of trimetazidine in the treatment of heart failure in hypertrophic cardiomyopathy and its effect on cardiac function of patients. Methods A total of 86 patients with heart failure in hypertrophic cardiomyopathy admitted to our hospital from August 2015 to March 2018 were selected as the research objects and divided into control group and observation group by simple random method, with 43 cases in each group. The control group was treated with routine anti-heart failure treatment, while the observation group was treated with trimetazidine treatment on this basis. The clinical effects of the two groups and changes of cardiac function were compared. Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05). After treatment,the LVEF in both groups increased, the LVESd and LVEDd reduced, the levels of NT-ProBNP decreased, and those in the observation group were better than the control group(P<0.05). Conclusion Trimetazidine is effective in the treatment of heart failure in hypertrophic cardiomyopathy and can improve the indexes of cardiac function of patients, which is recommended to be popularized.
引文
[1]中国抗癌协会甲状腺癌专业委员会.甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J].中国肿瘤临床,2016,43(10):405-411.
[2]韦丙奇,黄燕,翟玫,等.32例肥厚型心肌病心力衰竭呈限制性心肌病改变患者的临床特点分析[J].中国循环杂志,2018,33(1):65-68.
[3]谢烨卿,陈瑞珍.2014欧洲心脏病学会肥厚型心肌病诊断及治疗指南更新要点[J].上海医药,2015,37(2):7-9.
[4]李品睿.肥厚型心肌病伴收缩性心力衰竭的临床特点及预后[D].大连:大连医科大学,2015.
[5]张二苗,王凌燕,王昕朋,等.少见非梗阻性肥厚型心肌病致舒张性心衰1例分享[J].中华急诊医学杂志,2017,26(8):981-982.
[6]顾敏,金汉,华伟,等.扩张期肥厚型心肌病16例患者心脏再同步化治疗的临床特征及疗效分析[J].中国循环杂志,2017,32(5):461-464.
[7]赵学军,王东阳.药物及导管消融治疗肥厚型心肌病合并心房颤动患者疗效及安全性对比研究[J].西北国防医学杂志,2017,39(5):324-327.
[8]郎旭东,黄伟.曲美他嗪治疗扩张型心肌病心力衰竭患者心功能的影响分析[J].中国地方病防治杂志,2017,32(2):187-189.
[2]韦丙奇,黄燕,翟玫,等.32例肥厚型心肌病心力衰竭呈限制性心肌病改变患者的临床特点分析[J].中国循环杂志,2018,33(1):65-68.
[3]谢烨卿,陈瑞珍.2014欧洲心脏病学会肥厚型心肌病诊断及治疗指南更新要点[J].上海医药,2015,37(2):7-9.
[4]李品睿.肥厚型心肌病伴收缩性心力衰竭的临床特点及预后[D].大连:大连医科大学,2015.
[5]张二苗,王凌燕,王昕朋,等.少见非梗阻性肥厚型心肌病致舒张性心衰1例分享[J].中华急诊医学杂志,2017,26(8):981-982.
[6]顾敏,金汉,华伟,等.扩张期肥厚型心肌病16例患者心脏再同步化治疗的临床特征及疗效分析[J].中国循环杂志,2017,32(5):461-464.
[7]赵学军,王东阳.药物及导管消融治疗肥厚型心肌病合并心房颤动患者疗效及安全性对比研究[J].西北国防医学杂志,2017,39(5):324-327.
[8]郎旭东,黄伟.曲美他嗪治疗扩张型心肌病心力衰竭患者心功能的影响分析[J].中国地方病防治杂志,2017,32(2):187-189.